CCCC
C4 Therapeutics Inc
NASDAQ: CCCC · HEALTHCARE · BIOTECHNOLOGY
$2.83
+10.55% today
Updated 2026-04-30
Market cap
$281.02M
P/E ratio
—
P/S ratio
7.82x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $4
Volume
3.0M
C4 Therapeutics Inc (CCCC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-16.98M | $55.61M | $-67.25M | $-86.97M | $-105.94M | $-106.84M | $-65.16M | $-98.69M |
| Capital expenditures | $2.69M | $1.35M | $650000.00 | $1.28M | $5.50M | $1.71M | $180000.00 | $607000.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $582000.00 | $1.64M | $3.43M | $21.51M | $30.02M | $27.23M | $29.66M | $19.10M |
| Free cash flow | $-19.67M | $54.27M | $-67.90M | $-88.24M | $-111.44M | $-108.55M | $-65.34M | $-99.30M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $11.97M | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $91.18M | $-104.90M | $-46.37M | — | — | — |